Skip to main content

Breyanzi® is THE ONE studied in a broad range of patients, including older patients with moderate comorbidities, as well as young and fit patients1-5

The TRANSFORM trial enrolled transplant-eligible patients who were R/R ≤12 months. Patients were allowed to cross over to receive Breyanzi. The PILOT trial enrolled transplant-ineligible patients, regardless of time to relapse. Bridging therapy was permitted in both Breyanzi 2L LBCL trials.
Patients of Breyanzi

In R/R LBCL trials, response rates were observed across patient subgroups, regardless of age, fitness status, response to prior therapy, or receipt of bridging therapy2,4,6,7

*Patient ages in TRANSFORM and PILOT ranged from 20 to 75 years and 53 to 84 years, respectively.1

2L, second-line; LBCL, large B-cell lymphoma; R/R, relapsed or refractory.

TRANSFORM and PILOT patient eligibility criteria

In the 3L+ TRANSCEND trial, patients were refractory or relapsed after ≥2 prior therapies, ≥18 years old, ECOG PS ≤2, LVEF ≥40%, CrCl ≥30 mL/min, and ALT ≤5x ULN.1

Treatment center

Identify eligible patients early and connect them with a CAR T-cell therapy treatment center

†Median age was 59 years (range: 20-75 years).1

‡Eligible patients for the PILOT trial were required to be ≥18 years old. Median age was 74 years (range: 53-84 years).1,3

§PILOT criteria included ALT/AST.1

3L, third-line; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CAR, chimeric antigen receptor; CrCl, creatinine clearance; DLCO, diffusing capacity of the lungs for carbon monoxide; ECOG PS, Eastern Cooperative Oncology Group performance status; LVEF, left ventricular ejection fraction; ULN, upper limit of normal.

Choose Breyanzi, THE ONE CAR T for the broadest range of patients with 2L LBCL1

Hypothetical Breyanzi LBCL patient Charlotte

Charlotte, 60 years old*

2L transplant eligible, R/R ≤12 months

Active, fit, and chemo-sensitive8

Charlotte is a married interior designer who is heavily involved in her local community. She wants to avoid high-dose chemotherapy and transplant.

Response to prior therapy

Response to prior therapy

  • CR to DA-EPOCH-R; relapsed at 11 months
Additional risk factors

Additional risk factors

  • Double-hit lymphoma
  • No relevant comorbidities
Clinical fitness

Clinical fitness

  • ECOG PS 0
  • LVEF 55%
  • CrCl 70 mL/min
  • Normal bone marrow reserve
  • ANC: 4 × 103 cells/μL
  • Platelets: 400 × 103/μL
Hypothetical Breyanzi LBCL patient Laurie

Laurie, 68 years old

2L transplant eligible, R/R ≤12 months

Fit, with additional risk factors8

Laurie is a former social worker who is enjoying retirement. She is eager to receive treatment that is right for her.

Clinical fitness

Clinical fitness

  • ECOG PS 1
  • LVEF 55%
  • CrCl 60 mL/min
  • Normal bone marrow reserve prior to R-CHOP

All patients depicted are hypothetical.

ANC, absolute neutrophil count; CR, complete response; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine.

Hypothetical Breyanzi LBCL patient Luke

Luke, 52 years old

2L transplant ineligible, regardless of time to relapse

Active

Luke is a published author and motivational speaker. He likes taking his dog out for walks, lives an active life, and does not want to plan around chemotherapy appointments.

Response to prior therapy

Response to prior therapy

  • Refractory disease to 4 cycles of R-CHOP
Additional risk factors

Additional risk factors

  • 1 extranodal site
  • Poor bone marrow reserve
Clinical fitness

Clinical fitness

  • ECOG PS 1
  • LVEF 45%
  • CrCl 55 mL/min
Hypothetical Breyanzi LBCL patient Betty

Betty, 72 years old

2L transplant ineligible, regardless of time to relapse

Betty is a widowed retired school teacher who recently moved in with her daughter’s family. She is interested in receiving treatment that will give her a chance for remission.

Response to prior therapy

Response to prior therapy

  • Relapsed at 18 months
Additional risk factors

Additional risk factors

  • Diabetes/impaired renal function
Clinical fitness

Clinical fitness

  • ECOG PS 1
  • LVEF 45%
  • CrCl 45 mL/min
  • Normal bone marrow reserve

All patients depicted are hypothetical.

R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine.

Hypothetical Breyanzi LBCL patient Robin

Robin, 56 years old

Original diagnosis: de novo DLBCL

Robin is a florist in a small city who lives with her spouse. Her 3 adult children live nearby. Robin is knowledgeable about her disease and treatment and is motivated to undergo treatment.

Response to prior therapy

Response to prior therapy

First-line therapy

  • Underwent chemoimmunotherapy; achieved CR
  • Relapsed at 18 months

Second-line therapy

  • Underwent high-dose chemotherapy and ASCT
  • Relapsed after 6 months
Additional risk factors

Additional risk factors

  • One extranodal site
  • Renal impairment
Clinical fitness

Clinical fitness at second line

  • ECOG PS 1
  • LVEF 56%
  • CrCl 52 mL/min

All patients depicted are hypothetical.

ASCT, autologous stem cell transplantation; CR, complete response; DLBCL, diffuse large B-cell lymphoma.

References

  1. Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025.
  2. Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-2308.
  3. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066-1077. doi:10.1016/S1470-2045(22)00339-4
  4. Crombie JL, Nastoupil LJ, Andreadis C, et al. Multicenter, real-world study in patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel in the United States. Presented at: American Society of Hematology Annual Meeting & Exposition; December 9, 2023; San Diego, CA. Presentation 104.
  5. CADTH Reimbursement Review. Lisocabtagene maraleucel (Breyanzi). Can J Health Tech. 2022;2(10).
  6. Nastoupil L, Kamdar M, Chavez JC, et al. Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymhpoma (LBCL) from the study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy. Presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2023; Chicago, IL.
  7. Abramson J, Solomon S, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Supplementary appendix. Blood. 2023;141(14):1675-1684.
  8. Chen AI, Maziarz RT. Can we truly define 'fitness' for CAR-T therapy in large B cell lymphoma patients? Chin Clin Oncol. 2024;13(1):15. doi:10.21037/cco-23-78
References

Important Safety Information

Indications

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

  • adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:
  • refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or
  • refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or
  • relapsed or refractory disease after two or more lines of systemic therapy.

Limitations of Use: BREYANZI is not indicated for the treatment of patients with primary central nervous system lymphoma.

Important Safety Information

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.
  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed.
  • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI.

Cytokine Release Syndrome

Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 702 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 54% of patients, including ≥ Grade 3 CRS in 3.2% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 98% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (≥10%) were fever, hypotension, tachycardia, chills, hypoxia, and headache.

Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI.

Neurologic Toxicities

Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred.

In clinical trials of BREYANZI, CAR T cell-associated neurologic toxicities occurred in 31% of patients, including ≥ Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7 days (range: 1 to 119 days). Of patients developing neurotoxicity, 82% also developed CRS.

The most common neurologic toxicities (≥5%) included encephalopathy, tremor, aphasia, headache, dizziness, and delirium.

CRS and Neurologic Toxicities Monitoring

Monitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time.

Hypersensitivity Reactions

Allergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO).

Serious Infections

Severe infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 34% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.7%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI.

Febrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

Monitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections.

Viral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.

Prolonged Cytopenias

Patients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration.

Hypogammaglobulinemia

B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 10% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated.

Live vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI.

Secondary Malignancies

Patients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS)

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines.

Adverse Reactions

The most common adverse reaction(s) (incidence ≥30%) in:

  • LBCL are fever, cytokine release syndrome, fatigue, musculoskeletal pain, and nausea. The most common Grade 3-4 laboratory abnormalities include lymphocyte count decrease, neutrophil count decrease, platelet count decrease, and hemoglobin decrease.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.

Bristol Myers Squibb logo
Legal Notice  Privacy Policy  Your Privacy Choices   Site Map  Contact Us

© 2026 Juno Therapeutics, Inc., a Bristol Myers Squibb company. All Rights Reserved.
BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.
Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

© 2026 Bristol Myers Squibb company.

2009-US-2600069

02/2026